Navigation Links
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Date:9/24/2007

ecialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine) extended release (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals Inc.; the successful development of JUVISTA(R) (hum
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Drug ... plant-derived compounds. BCC Research reveals in its new report that the U.S. ... defines the category and generates the most market demand. , BCC Research ...
(Date:9/2/2015)... BioLight Life Sciences Investments ... a firm that invests in, manages and commercializes ... today that presentations highlighting its IOPtiMate™ system for ... the Ophthalmology Futures European Forum and the XXXIII ... Refractive Surgeons ("ESCRS"), both taking place in the ...
(Date:9/2/2015)... ... 02, 2015 , ... Temarry Recycling's new $100,000 waste to ... process and continue to contribute to the sustainability of our natural resources. , ... process has been operating at their Mexico facility, Recicladora Temarry, for the last ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is now accepting ... program. LOIs are due no later than Wednesday, October ... Discovery Grants are one-year, $50,000 grants that fund high risk/high ... or treatment paradigms for adults and children with brain ... earliest stages, in the hopes that it spurs additional ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... SAN DIEGO, Jan. 19, 2011 LifeVantage Corporation ... science-based solutions to oxidative stress, announced preliminary unaudited net revenue ... net revenue of approximately $7.4 million for the three month ... approximately $1.0 million or 15% over net revenue of $6.4 ...
... Inc. (OTC Bulletin Board: RGIN ) a ... regenerative cell therapies to restore the health of damaged ... feedback from attendees following their presentations at the OneMedForum ... conference was CEO Randall McCoy and senior Board Members ...
... This release is available in German . ... Ralph G. Nuzzo paved the way for use of the ... without that innovation. Professor Nuzzo is now honored with the ... includes guest visits to the Institute of Functional Interfaces (IFG) ...
Cached Biology Technology:LifeVantage Announces Preliminary Unaudited Second Quarter 2011 Results 2LifeVantage Announces Preliminary Unaudited Second Quarter 2011 Results 3Regenicin Receives Positive Feedback at OneMedForum Conference 2New impulses for surface research 2
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... Ph.D., member of the Basic Sciences Division at Fred ... in the American Academy of Arts & Sciences, or ... honorary societies and independent policy-research centers.She is among 190 ... the AAAS 2008 class of fellows. Drawn from the ...
... The key focus of the Diogenes study is to identify ... after initial successful weight loss. To participate in the ... least 8% of their body weight, before the whole family ... and randomised to one of five diets. 763 ...
... -- Ronald Hoenig and Aaron Welch, both graduate ... School of Marine UM Rosenstiel School students take ... Competitionand Atmospheric Science, won first place in the ... Leigh Rothschild Entrepreneurship Competition. The two Marine ...
Cached Biology News:Nobel laureate Dr. Linda Buck elected to American Academy of Arts & Sciences 2008 Class of Fellows 2Nobel laureate Dr. Linda Buck elected to American Academy of Arts & Sciences 2008 Class of Fellows 3How to stop regaining weight? That's the real question 2Aquaculture concept leaves judges 'goggle eyed' 2
D4-GDI rabbit polyclonal antibody...
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Biology Products: